ePaper

Friday, April 20, 2018

Teaching drugs new tricks

  • Print

Producing effective medicines requires huge investments of time and money. The average drug on the market today spent a decade in the lab and in clinical trials, and cost more than $2 billion to develop. Unfortunately, most prescription drugs are marketed for a single disease, rather than a group of diseases for which they could be safe and effective. This increases development costs, and complicates the discovery of new drug applications.

Fortunately for patients everywhere - not to mention the pharmaceutical industry and health-care systems worldwide - there is a better approach. Similar to recycling of household goods, "systematic drug repositioning" seeks to make drugs developed for one illness capable of treating another.

That is the story of thalidomide, which was used in the 1950s and 1960s by pregnant women to allay morning sickness, but was banned after it was found to cause severe birth defects. After significant study, however, scientists modified the drug's molecular structure to alter how it works. Now, the thalidomide family of drugs is prescribed for multiple myeloma, mantle cell lymphoma, certain skin diseases, and some forms of anemia.

What is significant about thalidomide is that a new treatment emerged from the ashes of failure. Many patients are benefiting today because a few scientists and their financial backers took a chance on reconsidering a failed drug.Equally remarkable is the history of a new multiple sclerosis (MS) treatment, called dimethyl fumarate. Under the brand name Tecfidera, this compound generates some $3 billion in annual revenue, and has helped many patients manage a crippling disease.

Yet it was first created almost 200 years ago by a French chemist as a mold inhibitor for sofas and leather apparel. It was later used to treat psoriasis; but, because psoriasis is related to autoimmune deficiencies, it was eventually tested on other autoimmune disorders, including MS.

Most drug-repositioning successes have happened by chance, as was the case with thalidomide and dimethyl fumarate. But what would happen if researchers and drug companies collaborated to search systematically for new uses of existing drugs? Medically, the payoffs could be massive - bringing equally massive benefits to society.

Drugs work by targeting specific molecules in the body. In some cases, different diseases have the same "target" molecule. For example, Arzerra, which was developed to treat chronic lymphocytic leukemia, targets a protein called CD20. But this protein is also associated with MS, and researchers found during testing that ofatumumab, which is the active ingredient in the medicine, could be of benefit to MS and possibly other autoimmune patients.

Given the drug's potential for treating cancer, GlaxoSmithKline, which markets Arzerra, first licensed the rights to its use as a cancer drug to another pharmaceutical giant, Novartis. Then, in a subsequent and separate deal, the company licensed additional rights to Novartis for the repositioned use in treating MS.

For the pharmaceutical industry, this was a revolutionary approach. The typical business model is to license all of a drug's current and future uses, even if the drug's potential is unknown at the time. In the case of Arzerra, however, a new business opportunity was created by splitting the drug into two revenue-generating assets.

Repositioning does not usually happen smoothly. Clinical trials are slow, cumbersome, and costly; many drugs don't overcome the financial hurdles. Moreover, "off-label prescribing" presents marketing challenges. After encountering patients who don't respond to standard courses of treatment, doctors may want to dispense a repositioned drug, but often don't have enough data to make an informed decision.

Pharmaceutical and biotech companies like ours are working to make this process easier. We focus on finding new uses for existing drugs in a systematic manner, combining augmented and artificial intelligence (AI) to do so. Our goal is a future where every drug is mapped against every known disease, no matter how that drug came into existence. Not only is this critical for improved patient health; it is also financially prudent, given that repositioning can cut the time and expense of drug development in half.

Other stakeholders are also getting involved. For example, the MEPs Against Cancer group, as well as a handful of non-profit foundations and certain policymakers, are reviewing the current regulatory pathway in Europe, and are calling for new drug-development routes that complement existing ones.

In the near future, drugs may even be repositioned in real time, mapped to the unique needs of each patient. New technologies like AI and augmented reality could help doctors find alternative treatments for patients with difficult-to-treat illnesses or complex comorbidities.

To realize this future, however, systematic repositioning must be integrated into every pharmaceutical firm's business model. Fortunately, there are strong economic incentives for companies proactively to do just that. If they do, we may find ourselves on the cusp of another discovery: that leveraging biological interconnectedness to reposition systematically old and new drugs is the best way to improve health and reduce health-care costs worldwide.

Aris Persidis is President and Co-Founder of Biovista Inc. Andreas Persidis is CEO and Co-Founder of Biovista Inc

More News For this Category

Machu Picchu: the citadel of great Incas

| By
Don't remember when exactly I first came across the names Machu Picchu and Incas but definitely I heard about these magical place and people from my Peruvian friends during
Machu Picchu: the citadel of great Incas

Ousting Zuckerberg from Facebook may not be easy

| By
A lot of people these days think Facebook has become an incorrigible, toxic "regime of one-sided, highly profitable surveillance" under the near-absolute control of a "sovereign and singular ruler",
Ousting Zuckerberg from Facebook may not be easy

How forums for men can also negate extremism

| By and Zarin Rafiuddin
One of the interesting articles written on the Guardian was by Richard Godwin titled "Men after #MeToo: 'There's a narrative that masculinity is fundamentally toxic.'" Godwin explores a
How forums for men can also negate extremism

Syria conflict and hypocrisy of the western powers

| By and Mafizul Huq
Since its foundation in 1947 the CIA was involved in covert and overt actions in regime change or save regime in the Third world countries' governments so that
Syria conflict and hypocrisy of the western powers

The Commonwealth: where being a journalist can kill you

| By and William Horsley
Fifty-three Commonwealth heads of government will meet for a summit in London on Thursday this week. Lord Ahmad of Wimbledon, the UK Minister of State for the Commonwealth,

'The Crown' screenplays Queen Elizabeth's life-sketch

| By and Zoe Szathmary
Queen Elizabeth II is set to hit another milestone on April 21 when she will turn 92 years old.The British royal has been depicted in popular culture many
'The Crown' screenplays Queen Elizabeth's life-sketch

Ways to develop our pleasant mind

| By and Sujayendra Das
Now the world has come to such a state of affairs when we find that pleasant mind and laughter has totally deluded from the threshold of our societies. Question

Thoughts on Mujibnagar Day

| By and Mahbubar Rahman
Eminent French writer and activist Emile Zola (1840-1902) once said, "When a truth is buried underground, it grows, it chokes, it gathers such an explosive force that one day
Thoughts on Mujibnagar Day

Too many problems from too many exams

| By and Alamgir Khan
From the current situation of education in Bangladesh, it seems that there is no meaning of education except passing exams. Do our policymakers understand any more than this about

Commonwealth principles on freedom of expression and media role in good governance

| By
On 11 April 2018, in light of the forthcoming summit of Commonwealth Heads of Government in London, the Commonwealth Journalists Association and the Institute of Commonwealth Studies released
Commonwealth principles on freedom of  expression and media role in good governance

© 2018 The Asian Age